Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second most common cause of cancer-related death in both men and women in the United States1

  • When colorectal cancer is found at an early stage before it has spread, the 5-year relative survival rate is about 90%1
  • 41% of adults ages 45 and older are not up-to-date with CRC screening1

Overall lifetimerisk of CRC2

Top 5 cancers

by # of new cancer cases*³

Top 5 cancers

by # of new cancer deaths*³

*US, 2023

What Makes ColoSenseTM Different?

ColoSense demonstrated high levels of sensitivity for colorectal cancer and advanced adenoma detection for a noninvasive test in a pivotal trial.

The CRC-PREVENT trial, published in The Journal of the American Medical Association in 2023, revealed4

Understanding RNA

ColoSense harnesses the power of RNA biomarkers for the qualitative detection of colorectal cancer and advanced adenomas.

  • ColoSense is a multi-target stool RNA (mt-sRNA) test engineered for the stabilization and qualitative detection of RNA signals
  • RNA biomarkers provide a dynamic view of disease activity, not subject to age-related methylation patterns that can lead to variability in test performance across different age groups5,6

RNA—Providing unique insights

  • Phenotypic
  • Quantitative and measurable
  • Real-time and dynamic

Stay Informed

Submit your information to stay informed about ColoSense and be the first to know when it becomes available to order.

*ColoSense is not yet available. By submitting your information, you agree to marketing communications that will include timely updates about the product and its availability.





I authorize Geneoscopy to send email:

Indication for Use and Important Risk Information and Limitations

Indication for Use

ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System.

ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy.

ColoSense is indicated as a screening test for adults 45 years of age or older who are at typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Important Risk Information and Limitations

The ColoSense test is not indicated for high-risk individuals, including patients with personal history of colorectal cancer, adenomas, or other related cancers. Positive result on another colorectal cancer screening method within the last six months, or: 12 months for fecal occult blood test (FOBT) or fecal immunochemical test (FIT), 36 months for FIT-DNA test. Have personal history of any of the following high-risk conditions for colorectal cancer: Inflammatory Bowel Disease (IBD), including chronic ulcerative colitis (CUC) and Crohn’s disease, Familial adenomatous polyposis (FAP), Family history of colorectal cancer, or other hereditary cancer syndromes including but not limited to: Hereditary non-polyposis colorectal cancer syndrome (HNPCC) or “Lynch Syndrome”, Peutz-Jeghers Syndrome, MUTYH Polyposis (MAP), Gardner’s Syndrome, Turcot’s (or Crail’s) Syndrome, Cowden’s Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.

The performance of ColoSense has been established in a prospectively designed, blinded, cross sectional, decentralized study. The benefits and risks of programmatic colorectal cancer screening (i.e., repeated testing over an established period of time) with ColoSense has not been studied. Non-inferiority or superiority of ColoSense programmatic sensitivity as compared to other recommended screening methods for colorectal cancer, advanced adenomas, or serrated precancerous lesions has not been established.

Precaution: No colorectal cancer screening test is perfect. ColoSense may produce false negative or false positive results. Based on the clinical validation data for ColoSense, with 25 / 27 colorectal cancers from typical average-risk patients identified (92.6%) and with a 95% two-sided confidence interval lower bound of 75.7%, there is a chance that as many as 24.3% of patients with colorectal cancer may be missed by this test, given the current data available.

  • A positive test result is recommended to be followed up by a colonoscopy. A false positive (incorrect) result occurs when ColoSense produces a positive result even though the individual does not have colorectal cancer or precancerous lesions.
  • A negative test result does not guarantee the absence of colorectal cancer or precancerous lesions. A false negative (incorrect) result may occur when ColoSense does not detect a colorectal cancer or precancerous lesion even though a colonoscopy could find colorectal cancer or precancerous lesions.

References

  1. Siegel  RL, Miller  KD, Wagle  NS, Jemal  A.  Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
  2. US Census data, Geneoscopy estimates (includes US markets only)
  3. American Cancer Society. Colorectal Cancer Facts & Figures 2023-2025. Atlanta: American Cancer Society; 2023.
  4. Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. 2023;330(18):1760–1768. doi:10.1001/jama.2023.22231
  5. Ahlquist, D. A., Taylor, W. R., Yab, T. C., Devens, M. E., Mahoney, D. W., Boardman, L. A., Thibodeau, S. N., Zou, H., Michael, D., Berger, B. M., & Lidgard, G. P. (2012). Abstract 3572: Methylated gene marker levels in stool: Effects of demographic, drug, and body mass and other patient characteristics. Cancer Research, 72(8_Supplement), 3572–3572. https://doi.org/10.1158/1538-7445.am2012-3572
  6. Ahlquist DA, Taylor WR, Yab TC, Devens ME, Mahoney DW, et al. (2012) Aberrantly Methylated Gene Marker Levels in Stool: Effects of Demographic, Exposure, Body Mass, and Other Patient Characteristics. J Mol Biomark Diagn 3:133. doi:10.4172/2155-9929.1000133

LBL-TD-0018 v0